Mauna Kea Technologies SA (MKEAF)
- Business Wire
On Target Laboratories and Mauna Kea Technologies Further Explore Targeted Detection and Real-Time Diagnosis of Lung Cancer with a Molecular Imaging Agent
WEST LAFAYETTE, Ind. & PARIS & BOSTON, July 26, 2022--Regulatory News: On Target Laboratories, Inc. (‘On Target’) a privately-held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery and Mauna Kea Technologies (Euronext: MKEA, ‘Mauna Kea’) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced publication of a study entitled
- Business Wire
Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues
PARIS & BOSTON, July 21, 2022--Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multi-disciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenues for the second quarter and first half of 2022 ended June 30, 2022.
- Business Wire
Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements
SHANGHAI & PARIS & BOSTON, July 11, 2022--Regulatory News: Webinar | July 12th 2022 at 6:00pm CEST (12:00pm EDT - New York)
